Drugs / AcSDKP-NH2
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT01588756 | Oct 2010 → May 2015 | chronic kidney disease | Assistance Publique - Hôpitaux de Paris | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AcSDKP-NH(2) | “AcSDKP-NH(2), an analogue of the endogenous tetrapeptide AcSDKP, is not degraded in vivo and is freely filtered by the kidney and eliminated in urine” PMID 22173804 ↗ Jan 2012 |
| Modality | Peptide | “Tetrapeptide N-acetyl-Ser-Asp-Lys-Pro-amide (AcSDKP-NH2)” NCT01588756 ↗ |
| Route | Intravenous | “AcSDKP-NH(2) was administered intravenously at a dose of 100 µg” PMID 22173804 ↗ Jan 2012 |